Publications of Tilia Marlene Zinnecker
All genres
Journal Article (2)
2024
Journal Article
24 (4), 2300245 (2024)
From single‐cell cloning to high‐yield influenza virus production – implementing advanced technologies in vaccine process development. Engineering in Life Sciences
Journal Article
20 (1), 2373521 (2024)
Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations. Human Vaccines & Immunotherapeutics Meeting Abstract (1)
2022
Meeting Abstract
Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors. In Proceedings Vaccine Technology VIII, 55. Vaccine Technology VIII, Sitges (Spain), June 12, 2022 - June 17, 2022. (2022)
Talk (8)
2024
Talk
Next-generation virus production: from clone, to AMBR, to perfusion and very high virus yield. 8th Edition of the "International Symposium on Immunobiologicals" (8th ISI), Rio de Janeiro (Brazil) (2024)
Talk
Influenza A Virus Production following Quality by Design Principles. Vaccine Technology IX, Los Cabos (Mexico) (2024)
2023
Talk
Intensified cell-based virus production: A process development challenge for multiple cell-virus combinations. 16th PEACe Conference, Sitges (Spain) (2023)
Talk
Next-Generation Virus Production: From Clone, to AMBR, to Perfusion and Very High Virus Yield. International Society for Vaccines (ISV) Annual Congress, Lausanne (Switzerland) (2023)
Talk
Increase in supply through use of new technologies for high yield vaccines. Flanders Vaccine, Brussels (Belgium) (2023)
Talk
Novel approach towards vaccine manufacturing: from single-cell cloning to high-yielding influenza virus production. 4th Global Bioprocessing, Bioanalytics and ATMP Manufacturing Congress, Dublin (Ireland) (2023)
Talk
A quest for the best influenza producing clonal MDCK cell line: intensifying by design of experiments, ambr15 and bench-top bioreactor cultivations. World Biopharm Forum 2023 - Democratisation of biotherapies: new manufacturing modalities and intensifications, Oxford (United Kingdom) (2023)
2022
Talk
Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors. Vaccine Technology VIII, Sitges (Spain) (2022)
Poster (5)
2024
Poster
Influenza A Virus Production following Quality by Design Principles. Vaccine Technology IX, Los Cabos (Mexico) (2024)
Poster
Implementation of Quality by Design Principles for Influenza A Virus Production. 28th ESACT Meeting, Edingburgh (Scotland) (2024)
2022
Poster
Generation and screening of monoclonal suspension MDCK cells for high-yield influenza A virus production. 3rd ESACT Frontiers Retreat, Vienna, Austria (2022)
Poster
Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors. Vaccine Technology VIII, Sitges (Spain) (2022)
Poster
Suspension MDCK cell line development by automated single-cell cloning & scale-down into ambr®15 microbioreactors in chemically defined medium. 27th ESACT Meeting, Lisbon (Portugal) (2022)
Thesis - Master (1)
2021
Thesis - Master
Single-Cell Analysis of Influenza A Virus Defective Interfering Particle Infection. Master, Technische Universität, Berlin (2021)